vs
Side-by-side financial comparison of Incyte (INCY) and Roper Technologies (ROP). Click either name above to swap in a different company.
Roper Technologies is the larger business by last-quarter revenue ($2.1B vs $1.3B, roughly 1.6× Incyte). Incyte runs the higher net margin — 23.8% vs 15.8%, a 8.0% gap on every dollar of revenue. On growth, Incyte posted the faster year-over-year revenue change (20.9% vs 11.3%). Over the past eight quarters, Roper Technologies's revenue compounded faster (10.5% CAGR vs 10.4%).
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
INCY vs ROP — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $2.1B |
| Net Profit | $303.3M | $331.0M |
| Gross Margin | — | 69.4% |
| Operating Margin | 23.7% | 27.2% |
| Net Margin | 23.8% | 15.8% |
| Revenue YoY | 20.9% | 11.3% |
| Net Profit YoY | 91.7% | 53.7% |
| EPS (diluted) | $1.47 | $4.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | $2.1B | ||
| Q4 25 | $1.5B | $2.1B | ||
| Q3 25 | $1.4B | $2.0B | ||
| Q2 25 | $1.2B | $1.9B | ||
| Q1 25 | $1.1B | $1.9B | ||
| Q4 24 | $1.2B | $1.9B | ||
| Q3 24 | $1.1B | $1.8B | ||
| Q2 24 | $1.0B | $1.7B |
| Q1 26 | $303.3M | $331.0M | ||
| Q4 25 | $299.3M | $428.4M | ||
| Q3 25 | $424.2M | $398.5M | ||
| Q2 25 | $405.0M | $378.3M | ||
| Q1 25 | $158.2M | $331.1M | ||
| Q4 24 | $201.2M | $462.3M | ||
| Q3 24 | $106.5M | $367.9M | ||
| Q2 24 | $-444.6M | $337.1M |
| Q1 26 | — | 69.4% | ||
| Q4 25 | 92.0% | 69.5% | ||
| Q3 25 | 92.8% | 69.5% | ||
| Q2 25 | 93.5% | 69.2% | ||
| Q1 25 | 93.0% | 68.7% | ||
| Q4 24 | 92.5% | 68.3% | ||
| Q3 24 | 92.4% | 69.2% | ||
| Q2 24 | 92.7% | 69.5% |
| Q1 26 | 23.7% | 27.2% | ||
| Q4 25 | 22.3% | 28.6% | ||
| Q3 25 | 32.5% | 28.4% | ||
| Q2 25 | 43.6% | 28.2% | ||
| Q1 25 | 19.5% | 27.9% | ||
| Q4 24 | 25.6% | 28.0% | ||
| Q3 24 | 12.8% | 28.1% | ||
| Q2 24 | -45.8% | 28.8% |
| Q1 26 | 23.8% | 15.8% | ||
| Q4 25 | 19.9% | 20.8% | ||
| Q3 25 | 31.1% | 19.8% | ||
| Q2 25 | 33.3% | 19.5% | ||
| Q1 25 | 15.0% | 17.6% | ||
| Q4 24 | 17.1% | 24.6% | ||
| Q3 24 | 9.4% | 20.8% | ||
| Q2 24 | -42.6% | 19.6% |
| Q1 26 | $1.47 | $4.87 | ||
| Q4 25 | $1.46 | $3.97 | ||
| Q3 25 | $2.11 | $3.68 | ||
| Q2 25 | $2.04 | $3.49 | ||
| Q1 25 | $0.80 | $3.06 | ||
| Q4 24 | $0.90 | $4.29 | ||
| Q3 24 | $0.54 | $3.40 | ||
| Q2 24 | $-2.04 | $3.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $382.9M |
| Total DebtLower is stronger | — | $9.7B |
| Stockholders' EquityBook value | $5.6B | $18.8B |
| Total Assets | $7.3B | $34.6B |
| Debt / EquityLower = less leverage | — | 0.52× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $382.9M | ||
| Q4 25 | $3.1B | $297.4M | ||
| Q3 25 | $2.5B | $320.0M | ||
| Q2 25 | $2.0B | $242.4M | ||
| Q1 25 | $1.9B | $372.8M | ||
| Q4 24 | $1.7B | $188.2M | ||
| Q3 24 | $1.3B | $269.6M | ||
| Q2 24 | $987.3M | $251.5M |
| Q1 26 | — | $9.7B | ||
| Q4 25 | — | $9.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $5.6B | $18.8B | ||
| Q4 25 | $5.2B | $19.9B | ||
| Q3 25 | $4.7B | $20.0B | ||
| Q2 25 | $4.2B | $19.6B | ||
| Q1 25 | $3.7B | $19.2B | ||
| Q4 24 | $3.4B | $18.9B | ||
| Q3 24 | $3.2B | $18.5B | ||
| Q2 24 | $3.0B | $18.1B |
| Q1 26 | $7.3B | $34.6B | ||
| Q4 25 | $7.0B | $34.6B | ||
| Q3 25 | $6.3B | $34.6B | ||
| Q2 25 | $5.8B | $33.2B | ||
| Q1 25 | $5.7B | $31.4B | ||
| Q4 24 | $5.4B | $31.3B | ||
| Q3 24 | $5.0B | $31.6B | ||
| Q2 24 | $4.7B | $29.8B |
| Q1 26 | — | 0.52× | ||
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | — |
| Free Cash FlowOCF − Capex | — | $507.0M |
| FCF MarginFCF / Revenue | — | 24.2% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $543.3M | $738.0M | ||
| Q3 25 | $559.4M | $869.5M | ||
| Q2 25 | $44.7M | $404.1M | ||
| Q1 25 | $266.1M | $528.7M | ||
| Q4 24 | $381.2M | $722.2M | ||
| Q3 24 | $310.9M | $755.4M | ||
| Q2 24 | $-575.6M | $384.1M |
| Q1 26 | — | $507.0M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | 24.2% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | 0.5% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.82× | 1.72× | ||
| Q3 25 | 1.32× | 2.18× | ||
| Q2 25 | 0.11× | 1.07× | ||
| Q1 25 | 1.68× | 1.60× | ||
| Q4 24 | 1.89× | 1.56× | ||
| Q3 24 | 2.92× | 2.05× | ||
| Q2 24 | — | 1.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
